Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “100 mg/5 mL Dosage and Administration: Intravenous infusion; 500 mg per dose. Dosage Schedule: Phase II: The single-dose group received a single dose on Day 1, and the double-dose group received a single dose on Day 1 and Day 15. Phase III: The dosing regimen will be determined based on the dose selected at the conclusion of Phase II: a single dose on Day 1 and Day 182, or a single dose on Day 1,…”In the company’s words, NCT07499700 on ClinicalTrials.gov
- Tested for
- Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS), Optic Neuromyelitis Spectrum Disease
- Main trialPhase 2/3
- “This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis”In the company’s words, NCT07499700 on ClinicalTrials.gov
Other drugs for Focal Segmental Glomerulosclerosis (FSGS)
- BI 764198Boehringer Ingelheim · Phase 3
- PropagermaniumDimerix Bioscience Pty Ltd · Phase 3
- BrivekimigSanofi · Phase 2
- FrexalimabSanofi · Phase 2
- RilzabrutinibSanofi · Phase 2
- PraliciguatAkebia Therapeutics · Phase 2
Coming up2
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 26 Oct 2030Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 26 Oct 2030 | A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis | |
| Phase 2Active, not recruiting | 31 Dec 2027 | A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders | |
| Phase 1Completed | 13 Mar 2023 | A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026